| Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ... New England Journal of Medicine 380 (12), 1103-1115, 2019 | 2254 | 2019 |
| Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... New England Journal of Medicine 383 (13), 1218-1230, 2020 | 1029 | 2020 |
| Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma A Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ... Journal of clinical oncology 31 (5), 616, 2013 | 892 | 2013 |
| Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma TK Choueiri, RJ Motzer, BI Rini, J Haanen, MT Campbell, B Venugopal, ... Annals of Oncology 31 (8), 1030-1039, 2020 | 399 | 2020 |
| Phase II study of the anti-cytotoxic T-lymphocyte–associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer KY Chung, I Gore, L Fong, A Venook, SB Beck, P Dorazio, PJ Criscitiello, ... Journal of Clinical Oncology 28 (21), 3485-3490, 2010 | 344 | 2010 |
| Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer NH Segal, AR He, T Doi, R Levy, S Bhatia, MJ Pishvaian, R Cesari, ... Clinical Cancer Research 24 (8), 1816-1823, 2018 | 238 | 2018 |
| Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors AW Tolcher, M Sznol, S Hu-Lieskovan, KP Papadopoulos, A Patnaik, ... Clinical Cancer Research 23 (18), 5349-5357, 2017 | 224 | 2017 |
| A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014 WA Messersmith, GI Shapiro, JM Cleary, A Jimeno, A Dasari, B Huang, ... Clinical Cancer Research 21 (1), 60-67, 2015 | 223 | 2015 |
| A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer M Aglietta, C Barone, MB Sawyer, MJ Moore, WH Miller Jr, C Bagalà, ... Annals of oncology 25 (9), 1750-1755, 2014 | 223 | 2014 |
| Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma BI Rini, M Stein, P Shannon, S Eddy, A Tyler, JJ Stephenson Jr, L Catlett, ... Cancer 117 (4), 758-767, 2011 | 192 | 2011 |
| Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with … P Zatloukal, DS Heo, K Park, J Kang, C Butts, D Bradford, S Graziano, ... Journal of Clinical Oncology 27 (15_suppl), 8071-8071, 2009 | 167 | 2009 |
| A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma C Papayannidis, DJ DeAngelo, W Stock, B Huang, MN Shaik, R Cesari, ... Blood cancer journal 5 (9), e350-e350, 2015 | 128 | 2015 |
| Maintenance avelumab+ best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 … T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... Journal of Clinical Oncology 38 (18_suppl), LBA1-LBA1, 2020 | 106 | 2020 |
| Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer MA Locatelli, P Aftimos, EC Dees, PM LoRusso, MD Pegram, A Awada, ... Oncotarget 8 (2), 2320, 2017 | 89 | 2017 |
| Alternative analysis methods for time to event endpoints under nonproportional hazards: a comparative analysis RS Lin, J Lin, S Roychoudhury, KM Anderson, T Hu, B Huang, LF Leon, ... Statistics in Biopharmaceutical Research 12 (2), 187-198, 2020 | 87 | 2020 |
| Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours M Millward, C Underhill, S Lobb, J McBurnie, SJ Meech, ... British journal of cancer 108 (10), 1998-2004, 2013 | 82 | 2013 |
| Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time‐to‐event end point B Huang, PF Kuan Pharmaceutical statistics 17 (3), 202-213, 2018 | 76 | 2018 |
| A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. NH Segal, AK Gopal, S Bhatia, HE Kohrt, R Levy, MJ Pishvaian, R Houot, ... Journal of Clinical Oncology 32 (15_suppl), 3007-3007, 2014 | 75 | 2014 |
| On the empirical choice of the time window for restricted mean survival time L Tian, H Jin, H Uno, Y Lu, B Huang, KM Anderson, LJ Wei Biometrics 76 (4), 1157-1166, 2020 | 73 | 2020 |
| Long-term follow-up of desmoid fibromatosis treated with PF-03084014, an oral gamma secretase inhibitor VM Villalobos, F Hall, A Jimeno, L Gore, K Kern, R Cesari, B Huang, ... Annals of Surgical Oncology 25, 768-775, 2018 | 62 | 2018 |
